Orphan opportunity

Private equity giant KKR returned to co-lead BridgeBio Pharma LLC's $135 million venture round, which could enable the Orphan play to double its pipeline in the next two years.

KKR co-led the Sept. 13 round with new investor Viking Global Investors. Other new investors included AIG, Aisling Capital, Cormorant Capital and Janus Funds. Existing investor Perceptive Advisors also participated. ...